NuzzoGGiulianteFArditoF, et al.Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg. 2012;147(1):26-34. doi:10.1001/archsurg.2011.771
2.
MuellerMBreuerEMizunoT, et al.Perihilar cholangiocarcinoma - novel benchmark values for surgical and oncological outcomes rom 24 expert centers. Ann Surg. 2021;274(5):780-788. doi:10.1097/SLA.0000000000005103
3.
YabushitaYParkJSYoonYS, et al.Conversion surgery for initially unresectable locally advanced biliary tract cancer: a multicenter collaborative study conducted in Japan and Korea. J Hepatobiliary Pancreat Sci. 2024;31(7):481-491. doi:10.1002/jhbp.1437
4.
OhDYHeARBouattourM, et al.Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694-704. doi:10.1016/S2468-1253(24)00095-5
5.
BismuthHNakacheRDiamondT. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215(1):31-38. doi:10.1097/00000658-199201000-00005
